What is The Association Between Honeycombing Appearance on CT and Life Expectancy in Patients with Scleroderma? A Comprehensive Systematic Review
Keywords:
Systemic sclerosis, scleroderma, honeycombing, interstitial lung disease, computed tomography, life expectancy, mortality, prognosisAbstract
Background: Systemic sclerosis (SSc) is a chronic autoimmune connective tissue disease with high morbidity and mortality, primarily driven by interstitial lung disease (ILD). Honeycombing on computed tomography (CT) represents irreversible fibrotic lung damage, but its precise relationship with life expectancy remains incompletely defined.
Methods: This systematic review synthesized evidence from 80 studies (198 individual cohorts in the primary meta-analysis) examining the association between honeycombing appearance on CT and survival outcomes in SSc patients. Data extraction focused on honeycombing assessment methods, patient characteristics, survival statistics, hazard ratios (HRs), and confounding factors.
Results: Honeycombing prevalence in SSc-ILD cohorts ranged from 37.2% to 41.9%, with higher frequency in limited cutaneous SSc. The systematic review by Haekal Mahargias et al. (2026) demonstrated that honeycombing was associated with a 2- to 3-fold increased mortality risk, with HRs ranging from 1.72 (95% CI 1.38–2.14) to 4.64 (95% CI 1.68–12.81). This association persisted after adjusting for age, gender, pulmonary function tests, and scleroderma subtype. Landini et al. (2022) found honeycombing extent was an independent predictor of respiratory mortality but not overall mortality. Radiographic progression (≥2% increase in quantitative ILD scores) predicted worse long-term survival (p=0.014 after adjustment). Baseline forced vital capacity (FVC) ≥70% was a strong protective factor (OR=0.039, 95% CI 0.002–0.616, p=0.02).
Discussion: Honeycombing represents irreversible fibrotic damage that outperforms ground-glass opacities in prognostic value. The association with mortality is partially mediated by pulmonary function decline, particularly FVC. Methodological heterogeneity in honeycombing assessment limits definitive conclusions. Current therapies (nintedanib, cyclophosphamide, mycophenolate) stabilize lung function but do not reverse established honeycombing. Patients with extensive honeycombing (≥50% lung involvement) are often excluded from therapeutic trials, creating selection bias.
Conclusion: Honeycombing on CT is a significant independent predictor of increased mortality in SSc-ILD, particularly respiratory-specific death. Standardized CT scoring systems with validated inter-rater reliability are urgently needed. Future prospective studies should examine honeycombing progression dynamics and develop honeycombing-specific therapeutic algorithms.
References
Haekal Mahargias, Febrina Mayasari Gunawan, Mutiara Amalia (2026) A Relationship Between The Honeycomb Appearance On Ct Scan And Life Expectancy In Patients With Scleroderma A Systematic Review. The Indonesian Journal of General Medicine. https://doi.org/10.70070/mkxj5n20
N. Landini, M. Orlandi, C. Bruni, et al (2022) Computed Tomography Predictors of Mortality or Disease Progression in Systemic Sclerosis–Interstitial Lung Disease: A Systematic Review. Frontiers in Medicine. https://doi.org/10.3389/fmed.2021.807982
C. Iannone, S. Stano, M. R. Pellico, et al (2025) ABS0860 FORCED VITAL CAPACITY AS AN INDEPENDENT SURVIVAL PREDICTOR IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY HYPERTENSION. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.06.1994
D. Khanna, C. Tseng, Niloofar Farmani, et al (2011) Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis & Rheumatism. https://doi.org/10.1002/art.30467
Y. Furuya, M. Kuwana (2011) Effect of Bosentan on Systemic Sclerosis-associated Interstitial Lung Disease Ineligible for Cyclophosphamide Therapy: A Prospective Open-label Study. Journal of Rheumatology. https://doi.org/10.3899/jrheum.110499
Tiffany A Winstone, D. Assayag, P. Wilcox, et al (2014) Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest. https://doi.org/10.1378/chest.13-2626
D. Tashkin, Michael D. Roth, Philip J. Clements, et al (2016) Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/S2213-2600(16)30152-7
E. Volkmann, D. Tashkin, Michael S. Roth, et al (2021) OP0267 SHORT-TERM CHANGES IN THE RADIOGRAPHIC EXTENT OF INTERSTITIAL LUNG DISEASE PREDICT LONG-TERM MORTALITY IN SYSTEMIC SCLEROSIS. https://doi.org/10.1136/ANNRHEUMDIS-2021-EULAR.1134
H. Kwon, E. Kang, J.K. Park, et al (2014) AB0622 Clinical Characteristics of Systemic Sclerosis Patients with Interstitial Lung Disease Who do not Require Immunosuppressive Treatment. https://doi.org/10.1136/annrheumdis-2014-eular.3686
E. Volkmann, D. Tashkin, P. Clements, et al (2015) SAT0444 Cyclophosphamide Versus Mycophenolate for Systemic Sclerosis-Related Interstitial Lung Disease. https://doi.org/10.1136/ANNRHEUMDIS-2015-EULAR.2081
K. Melissaropoulos, D. Daoussis, I. Antonopoulos, et al (2015) SAT0450 Rituximab in Systemic Sclerosis. Results of an up to Seven Years, Open Label, Multicenter Study with a Follow-up of 89 Patient-Years. https://doi.org/10.1136/annrheumdis-2015-eular.4618
Hao Cheng, Zhen Yu, Cheng-lan Yan, et al (2022) Long-Term Efficacy and Low Adverse Events of Methylprednisolone Pulses Combined to Low-Dose Glucocorticoids for Systemic Sclerosis: A Retrospective Clinical Study of 10 Years’ Follow-Up. Journal of Inflammation Research. https://doi.org/10.2147/JIR.S373387
B. Koo, K. Park, H. J. Lee, et al (2021) Effect of combined pulmonary fibrosis and emphysema on patients with connective tissue diseases and systemic sclerosis: a systematic review and meta-analysis. Arthritis Research & Therapy. https://doi.org/10.1186/s13075-021-02494-y
P. Fraticelli, B. Gabrielli, G. Pomponio, et al (2014) Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Research & Therapy. https://doi.org/10.1186/ar4606
A. Bérézné, D. Valeyre, B. Ranque, et al (2007) Interstitial Lung Disease Associated with Systemic Sclerosis. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1423.029
Luis Javier Cajas Santana, Diana Rocío Gil Calderón, M. Rubio Rivera, et al (2023) Progressive pulmonary fibrosis associated autoimmune diseases: Systematic review of the literature. Revista Colombiana de Reumatología. https://doi.org/10.1016/j.rcreu.2023.09.007
E. Volkmann, D. Tashkin, R. Silver, et al (2022) Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trials. The Lancet Rheumatology. https://doi.org/10.1016/s2665-9913(22)00193-x
S. Assassi, Sudhakar Tumuluri, Robert W Levin (2023) Interstitial lung disease in patients with systemic sclerosis: what can we learn from the SENSCIS trial? Clinical and Experimental Rheumatology. https://doi.org/10.55563/clinexprheumatol/trcv91
M. Strek (2018) Systemic sclerosis‐associated interstitial lung disease: Role of the oesophagus in outcomes. Respirology (Carlton South Print). https://doi.org/10.1111/resp.13335
O. Ovsyannikova, L. Garzanova, L. Ananyeva, et al (2021) AB0453 THE CHARACTERISTICS OF SSc-ILD PATIENTS WITH ACTIVE THERAPY IN DIFFERENT PROGNOSIS INTERVALS BASED ON DISCRIMINANT ANALYSIS. https://doi.org/10.1136/ANNRHEUMDIS-2021-EULAR.3589
E. Volkmann, H. Wilhalme, Sam Good, et al (2025) A composite endpoint for systemic sclerosis-associated interstitial lung disease: association with mortality in two clinical trial cohorts. Respiratory Research. https://doi.org/10.1186/s12931-025-03401-8
S. Wangkaew, H. Thongwitokomarn, N. Prasertwittayakij, J. Euathrongchit (2020) THU0368 RAPID SKIN THICKNESS PROGRESSION RATE IS ASSOCIATED WITH HIGH INCIDENCE RATE OF CARDIOPULMONARY INVOLVEMENT AND MORTALITY IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC). Annals of the Rheumatic Diseases. https://doi.org/10.1136/ANNRHEUMDIS-2020-EULAR.634
E. Volkmann, M. Sim, D. Tashkin, et al (2017) OP0124 Treatment with cyclophosphamide for systemic sclerosis-related interstitial lung disease does not improve survival after 12 years of follow up. https://doi.org/10.1136/ANNRHEUMDIS-2017-EULAR.2488
A. Vacca, P. Garau, G. Porru, et al (2013) FRI0384 Safety and efficacy of oral cyclophosphamide long-term therapy in systemic sclerosis: experience of a single-centre. https://doi.org/10.1136/annrheumdis-2013-eular.1511
D. Khanna, M. Roth, P. Clements, et al (2016) FRI0267 Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-Related Interstitial Lung Disease: Scleroderma Lung Study II. https://doi.org/10.1136/ANNRHEUMDIS-2016-EULAR.2126
A. Balbir-Gurman, L. Guralnik, M. Yigla, et al (2013) FRI0385 Long term follow-up after systemic sclerosis patients treated with intravenous cyclophosphamide pulse therapy for interstitial lung disease: a single eustar center (042) experience. https://doi.org/10.1136/annrheumdis-2013-eular.1512
Zineb Barkhane, Fnu Nimerta, Sualeha Zulfiqar, et al (2023) Independent Predictors of Mortality in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Cureus. https://doi.org/10.7759/cureus.39730
D. Rossi, S. Sciascia, I. Cecchi, et al (2021) A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response. Journal of Clinical Medicine. https://doi.org/10.3390/jcm10020292
M. R. Pokeerbux, J. Giovannelli, Luc Dauchet, et al (2019) Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Research & Therapy. https://doi.org/10.1186/s13075-019-1867-1
E. Volkmann, D. Tashkin, Michael D. Roth, et al (2021) Early Radiographic Progression of Scleroderma. Chest. https://doi.org/10.1016/j.chest.2021.11.033
Giles Dixon, H. Thould, M. Wells, et al (2025) A systematic review of the role of quantitative CT in the prognostication and disease monitoring of interstitial lung disease. European Respiratory Review. https://doi.org/10.1183/16000617.0194-2024
M. Ghazipura, M. Macrea, D. Herman, et al (2023) Tocilizumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society. https://doi.org/10.1513/AnnalsATS.202301-056OC
J. Potjewijd, R. Tobal, D. Silvertand, et al (2022) Favorable long term effects of intensified immunosuppression combined with therapeutic plasma exchange in patients with early-onset progressive systemic sclerosis-related interstitial lung disease. Journal of Translational Autoimmunity. https://doi.org/10.1016/j.jtauto.2022.100174
J. Konma, T. Kotani, T. Shoda, et al (2018) Efficacy and safety of combination therapy with prednisolone and oral tacrolimus for progressive interstitial pneumonia with systemic sclerosis: A retrospective study. Modern Rheumatology. https://doi.org/10.1080/14397595.2018.1441658
Olga Ovsynnikova, O. Koneva, L. Garzanova, et al (2021) TO ASSESS DIFFERENT PROGNOSIS INTERVALS FOR PATIENTS WITH SYSTEMIC SCLEROSIS- INTERSTITIAL LUNG DISEASE. Chest. https://doi.org/10.1016/j.chest.2021.07.1155
M. Vonk, W. V. D. Hombergh, H. Knaapen, et al (2017) AB0652 Early organ involvement, survival and causes of death in an unselected cohort of dutch patients with systemic sclerosis. https://doi.org/10.1136/ANNRHEUMDIS-2017-EULAR.3426
M. Vonk, W. V. D. Hombergh, H. Knaapen, et al (2017) AB0652 Early organ involvement, survival and causes of death in an unselected cohort of dutch patients with systemic sclerosis. https://doi.org/10.1136/annrheumdis-2017-eular.3426
E. Volkmann, D. Tashkin, A. Fischer, et al (2016) FRI0274 Predictors of Survival in Patients with Systemic Sclerosis-Related Interstitial Lung Disease Enrolled in The Scleroderma Lung Study II. https://doi.org/10.1136/annrheumdis-2016-eular.2999
Jeewon Lee, Ahran Kim, Jung Hyun Nam, et al (2025) Clinical trajectories and outcomes of progressive pulmonary fibrosis in connective tissue disease associated interstitial lung disease (CTD-ILD). ILD/DPLD of known origin. https://doi.org/10.1183/13993003.congress-2025.pa6119
B. Griffiths, S. Miles, H. Moss, et al (2002) Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. Journal of Rheumatology
A. Hoffmann-Vold, T. Maher, E. Philpot, et al (2021) Assessment of recent evidence for the management of patients with systemic sclerosis-associated interstitial lung disease: a systematic review. ERJ Open Research. https://doi.org/10.1183/23120541.00235-2020
Ioannis Pakas, J. Ioannidis, K. Malagari, et al (2002) Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. Journal of Rheumatology
K. Ando, S. Motojima, T. Doi, et al (2013) Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease. Respiratory Investigation. https://doi.org/10.1016/j.resinv.2012.12.002
D. Khanna, Celia J. F. Lin, J. Goldin, et al (2019) OP0245 PRESERVATION OF LUNG FUNCTION OBSERVED IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC. Oral Presentations. https://doi.org/10.1136/annrheumdis-2019-eular.2120
L. Ananyeva, O. Desinova, M. Starovoytova, et al (2013) SAT0198 Rituximab for the Treatment of Systemic Sclerosis Associated Interstitial Lung Disease: a Case Series. https://doi.org/10.1136/ANNRHEUMDIS-2013-EULAR.1924
C. Campochiaro, G. de Luca, M. Lazzaroni, et al (2022) POS0890 NINTEDANIB REAL-LIFE EFFICACY AND SAFETY IN SYSTEMIC SCLEROSIS (SSc)-INTERTISTIAL LUNG DISEASE (ILD): AN ITALIAN MULTICENTRE PRELIMINARY STUDY. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2022-eular.3183
O. Ovsyannikova, L. Ananyeva, L. Garzanova, et al (2021) AB0455 MODIFICATION OF PROGNOSIS INTERVALS WAS DERIVED BY THE DISCRIMINATION FUNCTION FOR SSc-ILD PATIENTS. Annals of the Rheumatic Diseases. https://doi.org/10.1136/ANNRHEUMDIS-2021-EULAR.3627
C. Campochiaro, G. De Luca, M. Lazzaroni, et al (2024) POS0826 PREDICTORS OF RESPONSE AND LONG-TERM EFFICACY AND SAFETY OF NINTEDANIB IN SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE: DATA FROM AN ITALIAN MULTICENTRE STUDY. Scientific Abstracts. https://doi.org/10.1136/annrheumdis-2024-eular.3502
P. Fraticelli, G. Pomponio, B. Gabrielli, et al (2013) SAT0213 Low-Dose Imatinib in the Treatment of Scleroderma Pulmonary Involvement: Results of a Phase II Pilot Study. https://doi.org/10.1136/annrheumdis-2013-eular.1939
S. Mittoo, F. Wigley, R. Wise, et al (2011) Long Term Effects of Cyclophosphamide Treatment on Lung Function and Survival in Scleroderma Patients with Interstitial Lung Disease. Open Rheumatology Journal. https://doi.org/10.2174/1874312901105010001
Meihua Qiu, Xue-yuan Nian, L-L Pang, et al (2021) Prevalence and risk factors of systemic sclerosis‐associated interstitial lung disease in East Asia: A systematic review and meta‐analysis. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185X.14206
K. Akash (2019) AB0665 OUTCOME OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SCLERODERMA, A 5 YEAR PROSPECTIVE COHORT STUDY. Abstracts accepted for Publication. https://doi.org/10.1136/annrheumdis-2019-eular.1816
O. Ovsyannikova, O. Koneva (2014) AB0633 Association of Decrease Diffusing Lung Capacity with Progression Pulmonary Alterations by HRCT in Patients with Systemic Sclerosis over A Five-Year Period. https://doi.org/10.1136/ANNRHEUMDIS-2014-EULAR.5169
L. Ananyeva, O. Ovsyannikova, V. Lesnyak, et al (2014) AB0627 Slow Progressive Interstitial Lung Disease Associated with Systemic Sclerosis: Distinct Disease Phenotype? https://doi.org/10.1136/annrheumdis-2014-eular.3488
J. Vakhshoorzadeh, J. Lui, R. Sangani, et al (2023) Emphysema and interstitial lung disease in systemic sclerosis-related pulmonary hypertension. Respiratory Medicine. https://doi.org/10.1016/j.rmed.2023.107333
R. Harrington, R. Conway, R. Fahy (2024) Meta-analysis of rituximab treatment of systemic sclerosis related interstitial lung disease. ILD/DPLD of known origin. https://doi.org/10.1183/13993003.congress-2024.pa694
K. Sullivan, E. Goldmuntz, L. Keyes‐Elstein, et al (2018) Myeloablative Autologous Stem‐Cell Transplantation for Severe Scleroderma. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1703327
K. Au, D. Khanna, P. Clements, et al (2009) Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials. Current Rheumatology Reports. https://doi.org/10.1007/S11926-009-0016-2
Yuqi Hu, Hui Zhang, Fan Zhang, et al (2020) Survival and Prognostic Factors in Patients with Connective Tissue Diseases Associated Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. https://doi.org/10.37766/inplasy2020.8.0005
O. Ovsyannikova, O. Koneva, L. Ananieva, et al (2020) RELATIONSHIP BETWEEN LUNG FUNCITON TEST AND DIGITAL ULCERS (DUS) IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) OVER A FIVE-YEAR PERIOD. https://doi.org/10.1016/j.chest.2020.05.416
K. Al Oweidat, A. Abdulelah, Ahmad A. Toubasi, et al (2025) The Clinical Efficacy and Safety of Nintedanib in the Treatment of Interstitial Lung Disease Among Patients With Systemic Sclerosis: Systematic Review. Canadian Respiratory Journal. https://doi.org/10.1155/carj/1682546
R. Wiewrodt, N. Goh, C. Denton, et al (2021) Effect of nintedanib in patients with limited and extensive systemic sclerosis-associated interstitial lung disease (SSc-ILD): data from the SENSCIS trial. Pneumologie. https://doi.org/10.1055/s-0041-1723314
W. Lin, H. Yin, C. Jia, et al (2025) POS0594 DOUBLE POSITIVITY FOR ANTI-Ro52/TRIM21 AND ANTI-Ro60/SSA ANTIBODIES IS LINKED TO GREATER ORGAN INVOLVEMENT AND DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS: INSIGHTS FROM THE RENJI SCLERODERMA LONGITUDINAL COHORT. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.05.974
O. Ovsyannikova, O. Koneva, L. Ananieva, et al (2022) Relationship between digital ulcers and severity of lung function test in systemic sclerosis over a five-year period. Rheumatology Science and Practice. https://doi.org/10.47360/1995-4484-2022-450-454
O. Ovsyannikova, L. Ananyeva, O. Koneva, et al (2019) AB0217 ASSOCIATION OF EUROPEAN SCLERODERMA STUDY GROUP ACTIVITY INDEX (ESCSG-AI) WITH PROGRESSION PULMONARY ALTERATIONS BY HRCT IN PATIENTSWITH SYSTEMIC SCLEROSIS OVER A FIVE YEAR PERIOD. Abstracts Accepted for Publication. https://doi.org/10.1136/annrheumdis-2019-eular.6818
F. Bonella, S. Humphries, E. Hachulla, et al (2021) Changes in Imaging Markers in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib: Sub-Study of the SENSCIS Trial. Pneumologie. https://doi.org/10.1055/s-0041-1723309
S. Panopoulos, V. Poulia, V. Bournia, et al (2025) POS0940 LUNG CANCER RISK IS INCREASED BY MORE THAN FIVE-FOLD IN SYSTEMIC SCLEROSIS: LONG-TERM FOLLOW-UP DATA FROM AN INCEPTION COHORT. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.06.295
F. Moazedi-Fuerst, A. Lackner, S. Kreuzer, et al (2024) AB1202 SUCCESSFUL LONG-TERM TREATMENT OF SYSTEMIC SCLEROSIS BY HIGH-FREQUENT, LOW-DOSE B CELL DEPLETING THERAPY. Scientific Abstracts. https://doi.org/10.1136/annrheumdis-2024-eular.2994
R.P. Goswami, V. Kotha, M. Surya (2025) POS0680 COMPARATIVE SHORT AND LONG-TERM OUTCOME OF IMMUNOSUPPRESSIVE TREATMENT OF SCLERODERMA-INTERSTITIAL LUNG DISEASE: RESULTS FROM A FIVE-YEAR PERSPECTIVE. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.06.041
A. Komócsi, A. Vorobcsuk, R. Faludi, et al (2012) The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology. https://doi.org/10.1093/rheumatology/ker357
C. Denton, N. Goh, S. Humphries, et al (2022) Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial. Rheumatology. https://doi.org/10.1093/rheumatology/keac535
S. Bae, R. Saggar, M. Bolster, et al (2012) Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2011-200546
L. Beretta, M. Caronni, M. Raimondi, et al (2006) Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clinical Rheumatology. https://doi.org/10.1007/s10067-006-0254-x
O. Ovsyannikova, L. Ananyeva, O. Koneva, et al (2019) AB0218 CORRELATION BETWEEN IMMUNOLOGICAL PARAMETERS AND PULMONARY FUNCTION PARAMETERS IN THE PATIENTS WITH SSC AND ILD OVER 5 YEARFOLLOW UP STUDY. Abstracts Accepted for Publication. https://doi.org/10.1136/ANNRHEUMDIS-2019-EULAR.7932
Dionisio Pérez Campos, Miguel Estévez del Toro, Aisa Peña Casanovas, et al (2012) Are high doses of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis? Reumatología Clínica. https://doi.org/10.1016/j.reuma.2011.11.006
B. Yurttaş, S. S. Taflan, N. Saltoğlu, G. Hatemi (2020) AB0542 REACTIONS TO PNEUMOCOCCAL 13-VALENT VACCINE IN PATIENTS WITH BEHCET SYNDROME. https://doi.org/10.1136/ANNRHEUMDIS-2020-EULAR.5509
O. Koneva, L. Garzanova, O. Ovsyannikova, et al (2022) AB0727 Study of the indicators dynamics of the pulmonary functional tests (PFTs) and X-ray picture against during the 36-month immunosuppressive therapy (IST) of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2022-eular.4572
Oksana Karasova, V. Rodionova, Yeseniya Tarasova, et al (2025) Pulmonary function and proteolytic activity of blood in patients with systemic scleroderma. ILD/DPLD of known origin. https://doi.org/10.1183/13993003.congress-2025.pa1883
D. Rossi, I. Cecchi, S. Sciascia, et al (2018) SAT0477 Intensified b-cell depletion therapy in progressive systemic sclerosispatients: 24 months follow-up. Saturday, 16 JUNE 2018. https://doi.org/10.1136/annrheumdis-2018-eular.6241
O. Ovsyannikova, O. Koneva, L. Ananieva (2018) THU0419 Association of inflammatory markers c-reactive protein and erythrocyte sedimentation ratewith pulmonary function tests and european scleroderma study group activity index (ESCSG-AI) in systemic sclerosis – associated interstitial lung disease in follow up study. THURSDAY, 14 JUNE 2018: https://doi.org/10.1136/annrheumdis-2018-eular.4600
Downloads
Published
Issue
Section
License
Copyright (c) 2026 I Dewa Gede Satwika Putra, Wyka Faulani Hafizah Nur (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
